Table of contents
About this book
Incentives for innovation are particularly relevant in the pharmaceutical
industry where not all social needs provide equally profitable
opportunities and where most OECD countries try to implement diffe -
rent measures that promote research in these less profitable areas. The
lack of incentives for innovation is especially dramatic when we take
into account diseases affecting mostly low-income countries, and also
diseases affecting small groups of patients.
How can incentives be provided to deal with these less profitable acti -
vities when no clear markets exist for the innovations being introduced?
Some of the contributions of this book go into discussing alternative
mechanisms to substitute for these inexistent markets, and
situations where traditional instruments such as public procurement or
direct subsidies have proven totally insufficient. Also, this book discusses
the clear mismatch between the size of the markets being targeted and
the incentives being provided.